Free cash flow margin reached 33.7% in 2026Q3 and operating cash flow was 1.77x net income, but cumulative operating cash flow of roughly $47B trailed cumulative net income of roughly $53B over the period, suggesting cash conversion has been uneven and partly working-capital driven.
Eli Lilly and Company (LLY) cash flow statement — 30-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 30.64B | 16.81B | 8.82B | 4.24B | 7.59B | 7.37B | 6.5B | 4.84B | 5.52B | 5.62B | 4.85B | 2.96B | 4.46B | 5.74B | 5.3B | 7.23B | 6.86B | 4.34B | 7.3B | 5.15B | 3.98B | 1.91B | 2.87B | 3.65B | 2.07B | 3.66B | 3.73B | 2.62B | 2.63B | 2.4B | 1.99B |
| Operating CF Margin % | - | 25.8% | 19.58% | 12.43% | 26.58% | 26.01% | 26.49% | 21.67% | 25.7% | 28.11% | 22.86% | 14.85% | 22.73% | 24.81% | 23.47% | 29.79% | 29.71% | 19.85% | 35.81% | 27.66% | 25.34% | 13.07% | 20.71% | 28.98% | 18.69% | 31.72% | 34.35% | 26.19% | 28.47% | 30.05% | 28.46% |
| Operating CF Growth % | 525.82% | 90.67% | 107.96% | -44.1% | 2.98% | 13.33% | 34.38% | -12.45% | -1.62% | 15.76% | 63.63% | -33.51% | -22.26% | 8.11% | -26.67% | 5.51% | 58.15% | -40.57% | 41.54% | 29.64% | 107.77% | -33.31% | -21.31% | 76.11% | -43.45% | -1.87% | 42.44% | -0.38% | 9.56% | 20.54% | 9.14% |
| Net Income | 27.58B | 20.64B | 10.59B | 5.24B | 6.24B | 5.58B | 6.19B | 8.32B | 3.23B | -204.1M | 2.74B | 2.41B | 2.39B | 4.68B | 4.09B | 4.35B | 5.07B | 4.33B | -2.07B | 2.95B | 2.66B | 1.98B | 1.81B | 2.56B | 2.71B | 2.78B | 3.06B | 2.72B | 2.11B | -385.1M | 1.52B |
| Depreciation & Amortization | 2.17B | 2B | 1.77B | 1.53B | 1.52B | 1.55B | 1.32B | 1.23B | 1.61B | 1.57B | 1.5B | 1.43B | 1.38B | 1.45B | 1.46B | 1.37B | 1.33B | 1.3B | 1.12B | 1.05B | 801.8M | 726.4M | 597.5M | 548.5M | 493M | 454.9M | 435.8M | 439.7M | 490.4M | 509.8M | 543.5M |
| Stock-Based Compensation | 698.1M | 626M | 645.6M | 628.5M | 371.1M | 342.8M | 308.1M | 312.4M | 279.5M | 281.3M | 255.3M | 217.8M | 156M | 144.9M | 141.5M | 147.4M | 231M | 368.5M | 255.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | -1.85B | -1.71B | -2.68B | -2.34B | -2.19B | -802.3M | -134.5M | 62.4M | 326.8M | -787.9M | 439.5M | -748.4M | 36.8M | 265.9M | 126M | -268.5M | 559.7M | 189.9M | 442.6M | 122.9M | 346.8M | -347.5M | 772.4M | 130.9M | 346.5M | 273.8M | -442.7M | 27.1M | 25.4M | -293M | 207.3M |
| Other Non-Cash Items | 7.61B | 3.35B | 3.88B | 2.24B | 1.63B | 1.71B | -444.2M | -3.4B | 2.46B | 1.55B | 406.1M | 798.3M | 12.6M | -413.2M | -462.3M | 385.9M | -146.1M | -892.6M | 5.2B | 1.15B | 959.9M | 1.5B | 927.5M | 322.7M | 65.4M | 230.3M | -97.1M | -142.3M | -100.2M | 2.09B | -97.8M |
| Working Capital Changes | -5.57B | -8.09B | -5.38B | -3.06B | -800K | -1.01B | -747.4M | -1.69B | -2.38B | 3.2B | -484.1M | -1.14B | 483.5M | -393M | -51.2M | 1.25B | -185.5M | -956.9M | 2.35B | -117M | -795.3M | -1.95B | -1.24B | 83.8M | -1.54B | -77.4M | 777.7M | -425.8M | 109.1M | 480.4M | -185.1M |
| Change in Receivables | 0 | -7B | -2.16B | -2.45B | -299.6M | -1.28B | -1.35B | -127.2M | -10.76B | -357M | -5.09B | -4.99B | 117.4M | -152.7M | 361.8M | -188.8M | -319.1M | 0 | 799.1M | 0 | 243.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | -4.67B | -2.51B | -1.43B | -599.7M | -235.9M | -533.4M | -258.7M | 7.8M | -253.9M | -328.2M | -736.3M | -307.1M | -286.5M | -307.9M | 203.1M | 157M | -179M | 84.8M | 154.3M | -60.2M | 72.1M | -111.6M | -170.8M | -285.1M | -184.2M | 9.8M | 16.9M | -55.6M | -65.8M | -42.2M |
| Change in Payables | 0 | 10.19B | 2.61B | 4.27B | 1.33B | -1.01B | 1.27B | -477.7M | -284.5M | 916.3M | 819M | 461.6M | 0 | -70.3M | -336.1M | 591.4M | -363.9M | 0 | -184.7M | 927.2M | -936M | -1.46B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -30.41B | -10.97B | -9.3B | -7.15B | -3.76B | -2.87B | -2.26B | -8.08B | 1.91B | -3.78B | -3.14B | 26.8M | -3.91B | -2.07B | -2.83B | -4.82B | -3.16B | 142.8M | -7.27B | -4.33B | 608.4M | -2.22B | -684.8M | -1.33B | -2.47B | -3.96B | -1.06B | 1.09B | -293.9M | 809.7M | -468M |
| Capital Expenditures | -10.98B | -7.84B | -8.4B | -3.45B | -1.85B | -1.31B | -2.03B | -1.35B | -1.21B | -2.16B | -1.09B | -1.63B | -1.57B | -1.01B | -1.04B | -1.69B | -1.19B | -855M | -947.2M | -1.08B | -1.08B | -1.3B | -1.9B | -1.71B | -1.13B | -884M | -677.9M | -528.3M | -419.9M | -366.3M | -443.9M |
| CapEx % of Revenue | 12.7% | 12.03% | 18.66% | 10.1% | 6.5% | 4.63% | 8.27% | 6.06% | 5.63% | 10.83% | 5.15% | 8.15% | 7.98% | 4.38% | 4.62% | 6.97% | 5.14% | 3.92% | 4.65% | 5.81% | 6.87% | 8.86% | 13.7% | 13.56% | 10.21% | 7.66% | 6.24% | 5.28% | 4.55% | 4.59% | 6.34% |
| Acquisitions | -10.8B | -661M | -947.7M | -1.04B | -327.2M | -747.4M | -849.3M | -6.94B | 0 | -882.1M | -45M | -5.28B | -551.4M | -43.7M | -199.3M | -282.5M | -609.4M | -72.3M | -6.08B | -2.67B | 65.2M | 11.1M | -71.7M | 61.2M | 36.8M | 31.6M | 0 | 1.68B | 0 | 1.23B | -97.1M |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -7.77B | -2.79B | 303.1M | -2.53B | -1.34B | -644.3M | 102.8M | -248.7M | -2B | -175.1M | -56.7M | 5.77B | -5.41B | 800K | 1.3B | -277.2M | -194.7M | -4.5M | -381.1M | -245M | 179M | -353.6M | -477.6M | -217.2M | -316.1M | -369.7M | -1.36B | -116.6M | -89.5M | -34.2M | -29.6M |
| Cash from Financing | -5.14B | -2.21B | 1.23B | 3.5B | -5.41B | -4.13B | -3.14B | -2.32B | -5.9B | 142.6M | -559.8M | -2.92B | -166.4M | -3.83B | -4.42B | -2.37B | -2.02B | -5.53B | 2.35B | -844.9M | -4.58B | -1.88B | 203.7M | -1.58B | -422M | -1.05B | -2.23B | -1.45B | -2.81B | -1.95B | -1.66B |
| Debt Issued (Net) | 7.32B | 8.05B | 8.9B | 8.65B | -62M | 501.4M | 291.6M | 4.69B | -729.3M | 3B | 2.5B | -181.6M | 2.64B | -10.5M | -1.51B | -195.8M | 124M | -3.42B | 4.41B | 984.6M | -2.79B | 6.6M | 1.64B | 42.7M | 1.23B | 594.7M | -229.1M | 690.6M | -176.4M | -1.15B | -811.8M |
| Equity Issued (Net) | -5.84B | -4.11B | -2.5B | -750M | -1.5B | -1.25B | -500M | -4.4B | -2.49B | -299.8M | -600.1M | -749.5M | -800M | -1.7B | -721.1M | 0 | 0 | 0 | 0 | 24.7M | -62.5M | -272M | 104.5M | -178M | -320.6M | -436.2M | -874.4M | -1.14B | -1.76B | 14.1M | -96.1M |
| Dividends Paid | -5.98B | -5.38B | -4.68B | -4.07B | -3.54B | -3.09B | -2.69B | -2.41B | -2.31B | -2.19B | -2.16B | -2.13B | -2.1B | -2.12B | -2.19B | -2.18B | -2.17B | -2.15B | -2.06B | -1.85B | -1.74B | -1.65B | -1.54B | -1.44B | -1.34B | -1.21B | -1.13B | -1B | -877.7M | -818M | -753.2M |
| Share Repurchases | -5.84B | -4.11B | -2.5B | -750M | -1.5B | -1.25B | -500M | -4.4B | -4.15B | -299.8M | -600.1M | -749.5M | -800M | -1.7B | -721.1M | 0 | 0 | 0 | 0 | 0 | -122.1M | -377.9M | 0 | -281.1M | -385.2M | -545.7M | -1.05B | -1.45B | -2.17B | -351.3M | -314.5M |
| Other Financing | -637.1M | -772M | -490.6M | -335M | -308.9M | -295.9M | -241.6M | -200.1M | -372.8M | -364.4M | -300.8M | 139.2M | 96.1M | 0 | 0 | 6M | 19.4M | 42.6M | -8.1M | -600K | 9.9M | 39.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | -4.91B | 4B | 449.8M | 751.6M | -1.75B | 161.4M | 1.32B | -5.66B | 1.46B | 1.95B | 915.7M | -205.2M | 41.4M | -188.6M | -1.9B | -70.7M | 1.53B | -1.03B | 2.28B | 111.2M | 102.6M | -2.36B | 2.61B | 810.4M | -756.4M | -1.41B | 414.5M | 2.2B | -451.8M | 1.13B | -185.8M |
| Free Cash Flow | 19.66B | 8.97B | 3.76B | -3.15B | 4.6B | 5.39B | 4.47B | 3.48B | 2.51B | 3.45B | 3.76B | 1.34B | 2.89B | 4.64B | 4.26B | 5.54B | 5.67B | 3.48B | 6.35B | 4.07B | 2.9B | 615.5M | 971.4M | 1.94B | 939.8M | 2.78B | 3.05B | 2.09B | 2.21B | 2.03B | 1.55B |
| FCF Margin % | 22.74% | 13.77% | 8.35% | -9.24% | 16.12% | 19.02% | 18.22% | 15.61% | 11.66% | 17.28% | 17.71% | 6.71% | 14.75% | 20.08% | 18.85% | 22.82% | 24.57% | 15.94% | 31.16% | 21.85% | 18.47% | 4.2% | 7.01% | 15.42% | 8.48% | 24.06% | 28.11% | 20.91% | 23.93% | 25.47% | 22.11% |
| FCF Growth % | 117.95% | 138.61% | 219.29% | -168.52% | -14.61% | 20.51% | 28.35% | 38.97% | -27.4% | -8.17% | 180.86% | -53.73% | -37.68% | 8.94% | -23.12% | -2.27% | 62.91% | -45.18% | 55.9% | 40.51% | 370.85% | -36.64% | -49.93% | 106.44% | -66.16% | -9.04% | 46.01% | -5.36% | 8.64% | 31.44% | 21.53% |
| FCF per Share | 22.01 | 9.99 | 4.16 | -3.49 | 4.84 | 5.65 | 4.67 | 3.64 | 2.42 | 3.28 | 3.41 | 1.21 | 2.60 | 4.16 | 3.72 | 4.97 | 5.13 | 3.17 | 5.80 | 3.73 | 2.67 | 0.56 | 0.89 | 1.80 | 0.87 | 2.55 | 2.79 | 1.89 | 1.97 | 1.80 | 1.39 |
| FCF Conversion (FCF/Net Income) | 0.71x | 0.81x | 0.83x | 0.81x | 1.21x | 1.32x | 1.05x | 0.58x | 1.71x | -27.51x | 1.77x | 1.23x | 1.87x | 1.22x | 1.30x | 1.66x | 1.35x | 1.00x | -3.52x | 1.75x | 1.49x | 0.97x | 1.59x | 1.42x | 0.76x | 1.32x | 1.22x | 0.96x | 1.25x | -6.23x | 1.31x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LLY stock.
Eli Lilly and Company (LLY) generated $16.81B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Eli Lilly and Company (LLY) generated $8.97B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Eli Lilly and Company (LLY) spent $7.84B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Eli Lilly and Company (LLY) returned $5.38B to shareholders via cash dividends and spent $4.11B on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Working capital driven cash volatility
Metrics are mathematically derived from official filings.
Cash Conversion Swings Driven by Working Capital
Based on LLY's reported figures, operating cash flow to net income ranged from 0.49x to 3.83x across ten quarters, with the latest quarter at 1.77x, indicating reported earnings have not translated into cash on a consistent basis.
The wide dispersion in the operating cash flow to net income ratio suggests that working capital timing, rather than underlying earnings quality, is driving most quarterly variation. The 2024Q3 reading of 3.83x alongside a sharply depressed net income of $970.3M appears to reflect timing effects rather than durable cash generation. Investors should monitor whether the 2026Q3 ratio of 1.77x reflects sustained collection improvement or a reversal of prior working capital build.
Free Cash Flow Margins Recovering Unevenly
As reported in quarterly cash flow statements, LLY's free cash flow margin moved from negative 12.6% in 2025Q1 to 33.7% in 2026Q3, but the path has been non-linear, with several quarters below 5%.
The trajectory suggests free cash flow has been highly sensitive to working capital movements, since operating cash flow swung from $1.7B to $11.4B over this window while capital expenditure remained comparatively steady near $2 to $3 billion per quarter. The 2026Q2 and 2026Q3 margins near 34% represent the strongest cash generation in the dataset, yet the preceding quarters indicate this level is not yet an established baseline. Investors should treat the recent run-rate with caution until it persists across additional reporting periods.
Capital Intensity Rising Alongside Manufacturing Build-Out
Based on LLY's reported figures, capital expenditure rose from roughly 10.3% of revenue in 2024Q3 to 13.2% in 2025Q4, consistent with continued investment in parenteral and fill-finish capacity.
A capex-to-revenue ratio in the low-to-mid teens is elevated for a company with an 84% gross margin, suggesting a meaningful share of cash flow is being redirected into physical capacity rather than distributed to shareholders. Depreciation and amortization of roughly $450 to $585 million per quarter remains well below capex, which implies the asset base is expanding rather than simply being maintained. This pattern may indicate that current cash generation is partly funding future volume capacity, a dynamic that warrants monitoring if demand growth moderates.
Acquisitions and Buybacks Absorb Excess Cash
As reported in cash flow statements, LLY deployed roughly $1.3 billion per quarter in dividends and between $0.4 billion and $2.4 billion in buybacks, with acquisition outflows of $8.7 billion in 2026Q2 standing out as the largest single deployment in the period.
The 2026Q2 acquisition outflow of $8.7 billion, which exceeded free cash flow for that quarter, suggests management prioritized inorganic growth despite strong operating cash generation. Combined dividends and buybacks in several quarters approached or exceeded free cash flow, which indicates shareholder returns may be partly funded from the balance sheet. The sustainability of this allocation pattern appears to depend on continued cash conversion rather than on the structural cash baseline.
Cumulative Cash Lags Reported Earnings
Based on LLY's reported figures, cumulative operating cash flow over the ten reported quarters totals roughly $47 billion against cumulative net income of roughly $53 billion, indicating a modest shortfall of cash relative to reported profit over the window.
A cumulative operating cash shortfall relative to net income over this sample suggests accruals and non-cash items have absorbed part of reported earnings during the period. Because the window is short and includes large swings in working capital, this gap should be read as a directional signal rather than a definitive measure of earnings quality. Investors should compare this gap against a longer history to determine whether the shortfall is cyclical or structural.
Recent Cash Strength May Not Persist
Based on LLY's reported figures, the 2026Q2 and 2026Q3 free cash flow margins near 34% sit far above the earlier 2024 to 2025 range, which may reflect a working capital release rather than a durable operating baseline.
If the recent cash surge partly reflects collection timing or a reversal of prior working capital build, the current run-rate could normalize and overstate sustainable free cash flow. The sharp decline in operating margin from its 2025Q3 peak of 47.6% to 35.3% in 2026Q3 further suggests that margin pressure may coexist with the cash improvement, warranting caution before extrapolating the latest quarters. Investors should weigh whether reported cash strength reflects structural earnings power or temporary balance sheet timing.